From the Woolfson Eye Institute, Atlanta, Georgia (Stulting); OVO LASIK + Lens, St. Louis Park, Minnesota (Lobanoff); Mann Eye Institute and Laser Centers, Houston, Texas (Mann); Washington University LASIK and Refractive Surgery Center, St. Louis, Missouri (Wexler); Laser Defined Vision, Greensboro, North Carolina (Stonecipher); Science in Vision, Bend, Oregon (Potvin).

Corresponding author: R. Doyle Stulting, MD, PhD, Woolfson Eye Institute, 800 Mt. Vernon Highway, NE Suite 120, Atlanta, GA 30328. Email: [email protected].

Disclosures: R. Potvin is a consultant to Alcon Laboratories, Inc. and Carl Zeiss Meditec AG. K. Stonecipher is a consultant to Acufocus, Inc., Alcon Laboratories, Inc., Allergan, Inc., Bausch Health Companies, Inc., Espansione, Eyevance, EyePoint Pharmaceuticals, Inc., Innovamed, Johnson & Johnson Vision, Kala Eyewear, Lombart, Marco, Nidek, Inc., Novartis Corp., Pogotec, Presbia Coöperatief U.A., and Refocus Ocular, Inc. S. Wexler is a consultant to Alcon Laboratories, Inc. and SiteOne Therapeutics, Inc. M. Lobanoff is a consultant to Alcon Laboratories, Inc. and is the founder/CEO of Phorcides LLC. R.D. Stulting is a consultant to Alcon Laboratories, Inc. P.M. Mann has no proprietary interest in the material presented.

First author:R. Doyle Stulting, MD, PhDWoolfson Eye Institute, Atlanta, Georgia